3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
10
Irinotecan
8
Cyclophosphamide
7
dinutuximab
5
aldesleukin
4
Interleukin-2
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
fludarabine
3
Topotecan
3
Melphalan
3
Isotretinoin
3
Filgrastim
3
gallium Ga 68 dotatate
2
Vincristine
2
TPI-287
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Carboplatin
2
venetoclax
1
trametinib
1
thymoglobulin
1
talazoparib
1
sonidegib
1
silmitasertib
1
plerixafor
1
olaparib
1
naxitamab
1
lutetium Lu 177 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neuroblastoma
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA